相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Second primary malignancies in multiple myeloma: A review
Christina Poh et al.
BLOOD REVIEWS (2021)
An Up-to-date Assessment of US Prostate Cancer Incidence Rates by Stage and Race: A Novel Approach Combining Multiple Imputation with Age and Delay Adjustment
Michael B. Cook et al.
EUROPEAN UROLOGY (2021)
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment The SYSUCC-001 Randomized Clinical Trial
Xi Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients
A. S. Rosenberg et al.
BLOOD CANCER JOURNAL (2021)
Racial Disparities and Trends in Pancreatic Cancer Incidence and Mortality in the United States
Anna Tavakkoli et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Updated Assessment of Colorectal Cancer Incidence in the US by Age, Sex, and Race/Ethnicity
Ajay Ohri et al.
DIGESTIVE DISEASES AND SCIENCES (2020)
Second malignancies in multiple myeloma; emerging patterns and future directions
Kylee Maclachlan et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2020)
Sex Differences in Cancer Incidence and Survival A Pan-Cancer Analysis
Michelle Dong et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2020)
Cervical Cancer Incidence and Mortality among Non-Hispanic African American and White Women, United States, 1999-2015
Sameer Vali Gopalani et al.
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION (2020)
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children
Veronique Minard-Colin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Incidence Trends of Breast Cancer Molecular Subtypes by Age and Race/Ethnicity in the US From 2010 to 2016
Teofilia Acheampong et al.
JAMA NETWORK OPEN (2020)
Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation
Satoshi Yamasaki et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2019)
Current status of autologous stem cell transplantation for multiple myeloma
Rama Al Hamed et al.
BLOOD CANCER JOURNAL (2019)
The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study
B. E. Oortgiesen et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
S. K. Kumar et al.
LEUKEMIA (2017)
Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study
Gudbjorg Jonsdottir et al.
HAEMATOLOGICA (2016)
Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study
Gudbjorg Jonsdottir et al.
HAEMATOLOGICA (2016)
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
J. R. Jones et al.
BLOOD CANCER JOURNAL (2016)
Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).
Michel Attal et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data
Antonio Palumbo et al.
LANCET ONCOLOGY (2014)
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
S. K. Kumar et al.
LEUKEMIA (2014)
Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups
S. Ailawadhi et al.
BLOOD CANCER JOURNAL (2014)
Time Trend of Multiple Myeloma and Associated Secondary Primary Malignancies in Asian Patients: A Taiwan Population-Based Study
Huey-En Tzeng et al.
PLOS ONE (2013)
Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics
P. Razavi et al.
BLOOD CANCER JOURNAL (2013)
Myeloid Neoplasms Secondary to Plasma Cell Myeloma: An Intrinsic Predisposition or Therapy-Related Phenomenon? A Clinicopathologic Study of 41 Cases and Correlation of Cytogenetic Features With Treatment Regimens
Deepti M. Reddi et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2012)
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
Philip L. McCarthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)
Sham Mailankody et al.
BLOOD (2011)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies
Erik von Elm et al.
ANNALS OF INTERNAL MEDICINE (2007)
Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms
C Dong et al.
BRITISH JOURNAL OF CANCER (2001)
分享论文
